Search clinical trials for: Comparator: niacin ( ) laropiprant (Source 2)

Total 277 results

Merck Sharp & Dohme LLC

Completed

MK0524A Bioequivalence Study (0524A-059)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy Study (0524B-022)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

Diabetes Mellitus Type 2
Merck Sharp & Dohme LLC

Terminated

Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) (ACHIEVE)

Hypercholesterolemia, Familial
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Cholesterol Levels (0524A-048)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

Flushing
Merck Sharp & Dohme LLC

Completed

MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

MK0524B Bioequivalence Study (0524B-070)

Dyslipidemia
Organon and Co

Completed

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy/Tolerability Study (0524A-020)

Primary Hypercholesterolaemia | Mixed Hyperlipidaemia
Instituto Aragones de Ciencias de la Salud
Hospital Miguel Servet

Completed

Effect of Niacin in the Lipoprotein (a) Concentration

Hypercholesterolemia

Spain
Rambam Health Care Campus

Unknown

The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker

Hypercholesterolemia

Israel
Calmy Alexandra
University Hospital, Geneva; Swiss National Science Foundation; Swiss Heart Foundation and other collaborators

Terminated

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

Atherosclerosis | HIV

Switzerland
Merck Sharp & Dohme LLC

Completed

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Mixed Dyslipidemia | Primary Hypercholesterolemia
University Medical Centre Ljubljana

Completed

Niacin/Laropiprant and Endothelial Function

Coronary Heart Disease

Slovenia
Merck Sharp & Dohme LLC

Terminated

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Hypercholesterolemia | Mixed Dyslipidemia
Daniel A. Siniawski
Merck Sharp & Dohme LLC

Terminated

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Coronary Artery Disease | Dyslipidemias

Argentina
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Withdrawn

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Dyslipidemia
Institut Investigacio Sanitaria Pere Virgili
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders

Completed

Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment (LOWHDL)

Type 2 Diabetes Mellitus | Dyslipidemia

Spain
Merck Sharp & Dohme LLC

Terminated

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Hypercholesterolemia, Familial | Heterozygous Familial Hypercholesterolemia
Ludwig-Maximilians - University of Munich

Terminated

Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Metabolic Syndrome | Hyperlipoproteinemia

Germany
Bayside Health
National Health and Medical Research Council, Australia

Terminated

Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease

Peripheral Arterial Disease

Australia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Sheba Medical Center

Terminated

The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients

Coronary Artery Disease | Dyslipidemia

Israel
AbbVie

Withdrawn

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Psoriasis
Tulane University
Patient-Centered Outcomes Research Institute

Recruiting

The Allergen Reduction and Child Health Study (ARCHS) (ARCHS)

Asthma in Children

United States
Eisai Inc.

Completed

Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Healthy | Drug Abuse

Canada
Bowen Chung, MD, MSHS
Tulane University; University of California, San Francisco; Louisiana State University... and other collaborators

Unknown

Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities) (RADD)

Depressive Symptoms

United States
Manchester University NHS Foundation Trust

Completed

Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers

Hypercholesterolemia

United Kingdom
Beijing Ditan Hospital

Completed

A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

SARS-CoV-2 Infection

China
Johns Hopkins University

Terminated

Effects of Repeated Memory Training on Memory Function and Addiction Related Processes

Substance-Related Disorders

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 (LILIADE-COVID)

COVID 19

France
Ursapharm Arzneimittel GmbH

Completed

Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis

Blepharitis | Signs and Symptoms

Ukraine
Wageningen University and Research

Completed

Health Effects of Sustainable Future Proteins (Su-Pro)

Protein Digestion Kinetics | Intestinal Barrier Function

Netherlands
George Thanassoulis
Jewish General Hospital; Laval University; Quebec Heart Institute

Withdrawn

Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL)

Aortic Stenosis and Lipoprotein(a) Levels

Canada
Eunice Kennedy Shriver National Institute of Child...

Terminated

Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

Obesity | Growth Hormone Deficiency | Short Stature

United States
Clinical Nutrition Research Center, Illinois Institute...

Completed

Bioavailability and Pharmacokinetics of Mango (MG)

Healthy Subjects

United States
Hull University Teaching Hospitals NHS Trust
Merck Sharp & Dohme LLC

Completed

Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

United Kingdom
University of Oxford
Merck Sharp & Dohme LLC

Completed

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE)

Cardiovascular Disease | Diabetes Mellitus | Peripheral Arterial Disease | Coronary Heart Disease

United Kingdom
Yooyoung Pharmaceutical Co., Ltd.

Withdrawn

Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee

Osteoarthritis, Knee

Korea, Republic of
Coloplast A/S

Completed

Explorative Clinical Study on the Performance and Acceptance of New Intermittent Catheters in Healthy Volunteers

Compliance, Patient

Denmark
Diakonhjemmet Hospital
Oslo University Hospital

Completed

Axillary Plexus Block in a High Resolution MRI

Magnetic Resonance Imaging | Nerve Block

Norway

3

Subscribe